MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study.

Beta-2-microglobulin (B2M) CLL IGVH mutations NOTCH1 Rai stage del11q del17p microRNA prognosis time to first treatment (TTFT)

Journal

Non-coding RNA

ISSN: 2311-553X

Titre abrégé: Noncoding RNA

Pays: Switzerland

ID NLM: 101652294

Informations de publication

Date de publication:
23 Aug 2024

Historique:

received: 25 07 2024

revised: 13 08 2024

accepted: 22 08 2024

medline: 23 9 2024

pubmed: 23 9 2024

entrez: 23 9 2024

Statut: epublish

Résumé

A "watch and wait" strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study, six well-established variables (i.e., Rai stage, beta-2-microglobulin levels,

Identifiants

DOI: 10.3390/ncrna10050046 PMID: 39311383

pubmed: 39311383

pii: ncrna10050046

doi: 10.3390/ncrna10050046

pii:

doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Italian Association for Cancer Research

ID : 5 × mille ID.9980

Organisme : Italian Association for Cancer Research

ID : I.G. ID.1426

Organisme : Italian Association for Cancer Research

ID : I.G. ID.24365

Organisme : Italian Association for Cancer Research

ID : I.G. ID.15426

Organisme : AIRC and Fondazione CaRiCal

ID : co-financed Multi-Unit Regional Grant 2014 n.16695

Organisme : Associazione Italiana Contro le Leucemie Linfomi e Mieloma

ID : AIL, Cosenza, to F.F.

Organisme : Gilead Sciences (Italy)

ID : fellowship program 2016

Organisme : Gilead Sciences (Italy)

ID : fellowship program 2017